Clinical Trials Legalization Microdosing Therapy 
Canna Law Blog
NOVEMBER 27, 2021
is expanding rapidly as numerous neuropharmaceutical companies look to be among the first-to-market potentially revolutionary therapies. In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. Compass Pathways Releases Phase 2B Trial Results.
Veriheal
MARCH 20, 2023
Alternative medicine is becoming more widely acknowledged and practiced than ever before, opening the door for therapies like psychedelics to enter the world of mainstream healthcare. Psilocybin therapy is both studied and used by highly legitimate medical establishments. Ned Lamont signed a bill (HB 5506) to fund psychedelic therapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
JANUARY 22, 2020
The company is also running a phase IIb clinical trial of its patented formulation, COMP360, which we covered in a blog post back in 2018. In that post, I explained how the Food and Drug Administration (FDA) approval process works and why this trial is so interesting and important. Psilocybin!
The Cannigma
DECEMBER 12, 2022
What is microdosing? A microdose is a dose that does not elicit a perceivable intoxicating or trip-like effect. At most, a mood boost should be all that is felt, and if any visual or auditory effects are noticeable then the dose is not, by definition, a microdose. Everyone is different. 19 20 21 22 23.
Cannabis Law Report
MARCH 3, 2022
The team at Microdose, the world’s biggest medical psychedelic conference , said the country’s move to permit Med Plant Science Ltd to produce psychedelic compounds makes it the first country to legalize all psychedelic medicine. . The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety.
Cannabis Law Report
NOVEMBER 24, 2019
Future studies will explore psilocybin’s effectiveness as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa, and alcohol use in people with major depression. Participate in Our Studies.
Cannabis Law Report
SEPTEMBER 10, 2019
Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression.
Expert insights. Personalized for you.
88 
Let's personalize your content